TY - JOUR
T1 - Epidemiological study of trichosporon asahii infections over the past 23 years
AU - Li, Haitao
AU - Guo, Meihong
AU - Wang, Congmin
AU - Li, Yibo
AU - Fernandez, Anne Marie
AU - Ferraro, Thomas N.
AU - Yang, Rongya
AU - Chen, Yong
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Trichosporon is a yeast-like basidiomycete, a conditional pathogenic fungus that is rare in the clinic but often causes fatal infections in immunocompromised individuals. Trichosporon asahii (T. asahii.) is the most common pathogenic fungus in this genus and the occurrence of infections has dramatically increased in recent years. Here, we report a systematic literature review detailing 140 cases of T. asahii infection reported during the past 23 years. Statistical analysis shows that T. asahii infections were most frequently reported within immunodeficient or immunocompromised patients commonly with blood diseases. Antibiotic use, invasive medical equipment, and chemotherapy were the leading risk factors for acquiring infection. In vitro susceptibility, clinical information, and prognosis analysis showed that voriconazole is the primary drug of choice in the treatment of T. asahii infection. Combination treatment with voriconazole and amphotericin B did not show superiority over either drug alone. Finally, we found that the types of infections prevalent in China are significantly different than those in other countries. These results provide detailed information and relevant clinical treatment strategies for the diagnosis and treatment of T. asahii infection.
AB - Trichosporon is a yeast-like basidiomycete, a conditional pathogenic fungus that is rare in the clinic but often causes fatal infections in immunocompromised individuals. Trichosporon asahii (T. asahii.) is the most common pathogenic fungus in this genus and the occurrence of infections has dramatically increased in recent years. Here, we report a systematic literature review detailing 140 cases of T. asahii infection reported during the past 23 years. Statistical analysis shows that T. asahii infections were most frequently reported within immunodeficient or immunocompromised patients commonly with blood diseases. Antibiotic use, invasive medical equipment, and chemotherapy were the leading risk factors for acquiring infection. In vitro susceptibility, clinical information, and prognosis analysis showed that voriconazole is the primary drug of choice in the treatment of T. asahii infection. Combination treatment with voriconazole and amphotericin B did not show superiority over either drug alone. Finally, we found that the types of infections prevalent in China are significantly different than those in other countries. These results provide detailed information and relevant clinical treatment strategies for the diagnosis and treatment of T. asahii infection.
UR - http://www.scopus.com/inward/record.url?scp=85089357839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089357839&partnerID=8YFLogxK
U2 - 10.1017/S0950268820001624
DO - 10.1017/S0950268820001624
M3 - Review article
C2 - 32703332
AN - SCOPUS:85089357839
SN - 0950-2688
JO - Epidemiology and Infection
JF - Epidemiology and Infection
ER -